Ambulatory Heart Failure Monitoring: A Systemic Review

Abstract

Heart failure (HF) is one of the leading causes of morbidity and mortality and has a large effect on the country’s economy. Although there have been major advances in HF monitoring, including more advanced pharmacological management and device-based therapy, HF-related mortality remains high. It is important to monitor HF so that HF-related hospitalization and mortality can be prevented. Due to the lower sensitivity of clinical features and biochemical markers, as well as the failure of telemonitoring in early detection of HF, more advanced techniques have been sought to more accurately predict impending HF, in order to address timely pharmacological management and prevent heart failure hospitalization (HFH). Device-based therapy has passed through various stages and culminated in the recently introduced CardioMEMSTM (St. Jude Medical, Inc., Saint Paul, Minnesota). CardioMEMSTM is a wireless pulmonary artery pressure (PAP) monitoring device, which continuously monitors PAP and transmits data to a healthcare provider. It rapidly identifies changes in intracardiac pressure and allows timely pharmacological management. CardioMEMSTM showed a higher reduction of HFH compared to any other devices.

The virtual physical exam in the 21st century

“…CardioMEMS™; Abbott Laboratories, Atlanta, GA) have introduced new variables to take objectively into a patient’s examination. 33…”

Reduction of Hospitalization and Mortality by Echocardiography-Guided Treatment in Advanced Heart Failure

“…However, clinical evaluation and lung auscultation may fail to detect subclinical HF decompensation [ 7 , 8 , 9 ]. On the other hand, intracardiac hemodynamic changes and an increase in LV filling pressure precede the manifestation of HF symptoms and can be detected by echocardiography [ 10 , 11 , 12 ]. Increased ventricular filling pressure results in high atrial pressure with subclinical HF deterioration [ 13 , 14 ].…”

Development and implementation of a remote patient monitoring program for heart failure: a single‐centre experience

“…1 Every hospitalization for acute decompensated HF (ADHF) is a predictor of readmission with a 1 month readmission rate of 30% and a 6 month readmission rate of 50%. 2 Hospitalization for HF is the leading cause of readmission within 60 days and is a strong predictor of mortality. [3][4][5] This highlights the importance of care coordination, patient monitoring, and early intervention to reduce HF hospitalizations and readmissions.…”

“…Heart failure (HF) affects approximately 26 million people worldwide with more than one million hospitalizations annually in both the USA and Europe, accounting for 1–2% of all hospital admissions 1 . Every hospitalization for acute decompensated HF (ADHF) is a predictor of readmission with a 1 month readmission rate of 30% and a 6 month readmission rate of 50% 2 . Hospitalization for HF is the leading cause of readmission within 60 days and is a strong predictor of mortality 3–5 .…”